Mumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for dif...

A recent investigation in Maharashtra has shed light on concerning price hikes for medical supplies charged to patients. Items such as IV i...

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicine...

The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in e...

The Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...

India should examine trade margins across medicines, medical devices and consumables using a common, scientifically credible method - not a...

India has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...

Sanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to ...

India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. ...

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...

The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...

Significant price differences in healthcare consumables have drawn attention, prompting calls for better consumer protection. Maharashtra's...

Supreme Court on Tuesday questioned the wide gap between the price to retailer and MRP of some cancer medicines, calling inflated pricing a...

Maharashtra FDA Commissioner Tukaram Mundhe has cited a survey showing substantial differences between procurement prices and printed MRPs ...

Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospi...

NPPA has initiated a process to end the freedom enjoyed by drug makers to fix the retail price of their imported medicines.

Drug price regulator the National Pharmaceutical Pricing Authority (NPPA) may lose some of its autonomy soon.